Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | JAK2 | O60674 | 3/20 | 0.39 |
| ▸ | ZAP70 | P43403 | 8/20 | 0.37 |
| ▸ | LYN | P07948 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1048184 | 0.92 | IGF1R (0.39) | EGFRJAK2ZAP70LYNSYK | |
| SCHEMBL1050089 | 0.91 | HTT (0.43) | EGFRJAK2SYK | |
| SCHEMBL1045744 | 0.90 | EGFR (0.34) | EGFRJAK2ZAP70LYNSYK | |
| SCHEMBL1046744 | 0.85 | HTT (0.38) | JAK2ALDH1A1 | |
| SCHEMBL1078959 | 0.85 | JAK2 (0.35) | EGFRJAK2ZAP70TTKMAPT | |
| SCHEMBL27826692 | 0.84 | ZAP70 (0.42) | JAK2ZAP70LYNSYKIDO1 | |
| SCHEMBL1048756 | 0.83 | ZAP70 (0.41) | JAK2ZAP70LYNSYKMAPT | |
| SCHEMBL1047792 | 0.82 | ZAP70 (0.37) | EGFRJAK2ZAP70LYNSYK | |
| SCHEMBL1048401 | 0.82 | ZAP70 (0.48) | JAK2ZAP70LYNSYK | |
| SCHEMBL1045695 | 0.81 | PDE1A (0.37) | ZAP70IDO1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546370-B2 | Compounds and compositions as kinase inhibitors | IRM LLC (BM) | 2013-10-01 | — | — | US | claimed |
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2011-01-06 | — | — | US | claimed |
| CN-101990539-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003798-A1 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | FYN, SYK, RET | EGFR 237/4885JAK2 63/4885ZAP70 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.